SlideShare a Scribd company logo
1
Forward Looking Statements
Statements made in this presentation include financial estimates and forward-looking statements that are not historical
facts. Each of these estimates and forward-looking statements involves risk and uncertainties. These estimates are based
on present circumstances, information currently available, and assumptions about future revenues, industry growth, and
general economic conditions. Estimates are inherently uncertain as they are based on assumptions concerning future
events. No representations can be made as to the accuracy of such information or the reliability of such assumptions.
Accordingly, actual revenues and expenditures may vary significantly from the Company’s estimates, and actual results or
developments may differ materially from those expressed or implied by the forward-looking statements. Factors that could
cause actual results to differ from the financial estimates and forward-looking statements in this presentation include those
described in the Company’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Therefore, neither the Company’s
estimates nor the assumptions upon which they are based are to be interpreted as a guarantee or promise of the Company
or management. The Company has no obligation to modify, amend, update, alter, or change the estimates contained
herein. The Company released its financial results for the year ended December 31, 2011 and first quarter ended 2012.
The Company’s 2012 revenue and EPS guidance is valid only as of the date it was given and is not being updated or
reaffirmed herein.

                        For more information, please contact:
                                      Anthony Scalese
                                  ascalese@zynexmed.com
                                          Zynex, Inc.
                                  9990 Park Meadows Drive
                                    Lone Tree, CO 80124
          Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynexmed.com


                                                                                                                           2
Zynex Overview
•   Develops, manufactures and markets non-invasive FDA-CE marked medical
    devices for pain relief, stroke/spinal cord rehabilitation, neurological and
    cardiac monitoring

•   Publicly Traded OTCBB: ZYXI
•   In operation since 1996
•   Headquartered in Lone Tree, Colorado

•   High revenue growth >50% CAGR since 1996 (2012 est. Revenue $40 million)
•   Profitable ($0.05 EPS 2011, $0.06-$0.08 EPS est. 2012)
•   $4B+ potential market

•   Ranked fastest growing medical equipment company in Rocky Mountain region and 9th fastest
    growing medical equipment company in US and Canada (Deloitte Fast 500)

ZYNEX MEDICAL (ZMI):
•  >70%+ recurring revenue with more than 40,000 units in the field
•  High GPM of >75%
•  Helped over 150,000 patients since inception

ZYNEX NEURODIAGNOSTICS (ZND):
•  Proprietary products (NeuroMove, NeuroDynamix-product line recently acquired)

ZYNEX MONITORING SOLUTIONS (ZMS):
•  Development of proprietary non-invasive blood volume monitor                                 3
Revenue Growth



                            >50% CAGR




* 2012 estimated revenue based on guidance previously provided
                                                                 4
Financial Summary
Annual Financial Data
                            2011      2010      2009      2008      2007     2006
   (000’s)

           Net Revenue     $34,148   $24,085   $18,681   $11,764   $8,048   $2,557

            Gross Profit   26,777    18,883    14,888     9,524    7,319    2,253

      Net Income (loss)     1,564     350       2,382     111      2,131    (320)

                    EPS     0.05      0.01      0.08      0.00      0.07    (0.01)

                   Cash     789       602       863         -        -       265

    Total Stock Holders
                           10,139     8,182     7,486     4,774    3,618    1,287
                 Equity


       Common Shares
                           31,000    30,600    30,500    29,900    26,800   26,300
          Outstanding




                                                                                     5
Financial Summary
Balance Sheet                           Mar-12           Dec-11           Dec-10

Cash                                              742              789             602
A/R                                         11,642            10,984           7,309
Inventory                                        5,580            4,557        3,641
Other Assets                                     1,691            1,718            980
 Current Assets                             19,655            18,048         12,532
PP&E                                             3,446            3,422        2,906
Other Assets                                      787              315             263
 TOTAL ASSETS                               23,888          $21,785         $15,701
Line of Credit                                   4,385            3,290        1,270
Other Liabilities                                6,937            6,460        4,282
 Current Liabilities                        11,322                9,750        5,552
Other Liabilities                                1,902            1,896        1,967
 Total Liabilities                          13,224            11,646           7,519
Common Stock                                       31               31             31
Paid-in-capital                                  5,300            5,095        4,702
Retained Earnings                                5,333            5,013        3,449
 Total Stockholders' Equity                 10,664            10,139           8,182
 Total Liab. And S.Equity                   23,888          $21,785         $15,701
Business Structure


                              ZYNEX, INC.



Current Revenue Driver       ~1% of Net Revenue                    R&D

    ZYNEX                     ZYNEX                              ZYNEX
                         NEURODIAGNOSTICS                      MONITORING
  MEDICAL INC.
                               INC.                           SOLUTIONS INC.




                         International Conduit for all Subs

                           ZYNEX EUROPE ApS


                                                                               7
History
1996                              Founded by Thomas Sandgaard

1999                      First Zynex-manufactured device cleared by FDA

2001            Shifted from wholesale-only to direct sales to physicians and Patients

2003   FDA clearance for full line of Electrotherapy Devices and NeuroMove stroke-rehab device

2004                             Reverse Merger into a Public shell

2008                        Receives European CE Mark on Key Products

                   Opens new 75,000 sq. ft. distribution and headquarters building
2010                             Establishes 2 new subsidiaries
                                 Added industry expert to Board

              Commenced clinical evaluations for blood volume monitor medical device.
2011                           Added Iontophoresis to product line
                    Received 510k clearance for next generation TENS device
                              Ramped up Zynex Medical sales force

          Completed asset acquisition of NeuroDyne, through Zynex NeuroDiagnostics Sub
2012                     Established European subsidiary, Zynex Europe
                  Submission to FDA for InWave device (incontinence treatment)       8
Available Market
                                    TAM ~ 4.0B




   Zynex Medical
                                       ~$550M
   Electrotherapy Devices



   Zynex Monitoring Solutions           ~$3B
   Cardiac Monitoring Devices



   Zynex NeuroDiagnostic                ~$900M
   Neurological Diagnosis Devices

                                                 9
Products

•Complete line of electrotherapy pain
management devices-FDA and EU
cleared

•Augments healing, alleviates swelling
through increased blood circulation,               NexWave
and reduces both acute/chronic pain
through the use of electrical currents             TruWave+

•Consumables required                               E-Wave

•Require a prescription                              IF8000

•Reimbursed by health insurance                      IF8100
(including Medicare/Medicaid)
                                                 Iontophoresis
•May be rented or purchased
                                               InWave (est. 2012)

                                         Consumables (battery/electrode) 10
Products


•Stroke/spinal cord rehabilitation
devices-FDA and EU cleared

•Augment healing, as well as assist in
recovery for stroke, Spinal Cord Injuries
and Traumatic Brain Injury, retrains
muscles, increases range of motion
                                                  NeuroMove
•Consumables required
                                                  Consumables
                                               (battery/electrode)

                                                    Sensors

                                            Other – acquisition/R&D



                                                                      11
Products


•Acquisition Mar 2012 (NeuroDyne Medical)-

•Non-invasive measurement devices for
surface electromyography (“sEMG”) and
autonomic nervous systems, used for
evaluation and treatment of neurological and
neuromuscular disorders as well as education
and research.


•Medial sensors required                       NeuroDynamix (acquired products)

                                                          Sensors

                                                Other – acquisition/R&D

                                                                                  12
Products


•In development – non invasive blood
volume monitor

•Used in operating and recovery rooms
to detect blood loss and internal bleeding

•Clinical trials commenced

•Patent filed

                                              Blood Volume Monitor
                                                  (in development)

                                             Other – acquisition/R&D


                                                                       13
Zynex Medical-Existing Business
                                                                                 Zynex-focus on
 Continued geographic                                                           customer service
 expansion for growth

                             Sales Representative      Doctor




                                                                                     More units in
    Zynex-proven     Zynex                                          Patient          field = greater
   system/process                                                                       recurring
                                                                                         revenue




                    Insurance Company                    Sales Representative
Barrier to entry
   for most

                                               Zynex
                                                                                             14
Competitive Advantage


Comprehensive Billing and                 Unique Technology                           Unique Technology
Reimbursement System                      NeuroMove medical device has                Blood Volume Monitor (in process) is
Accept and bill virtually all insurance   unique technology for stroke                anticipated to meet current unmet
plans, including Medicare                 rehabilitation (little to no competition)   needs in a significant cardiac
                                                                                      monitoring market (little to no
                                                                                      competition)
Breadth of Product offering               Breadth of Product offering
Range of products enables                 Newly acquired Neurodynamix
physicians and rehab facilities with a    systems offer a complete suite of
full suite of products for their          diagnostics software to serve market
patients                                  needs in a singular/modular format
                                          (same hardware)

Customer Service
                                          Customer Service
Superior post sale “hands on”
patient support for device education      Superior post sale “hands on”
and proper fitting – “Happy patient =     patient support for device education
Happy doctor”

Distribution Channels
Over 200 sales reps/fitters
domestically



                                                                                                                   15
Opportunities


•Sales channel expansion
(US & International)

• New products introduced
(NexWave & Iontophoresis,
InWave est. release 2012)

•Large recurring revenue
stream

•Comprehensive billing and
reimbursement system
/process (all third party
payors, government,
workers compensation)



                                             16
Zynex Medical-Opportunities



        3%
       1%    6%
 10%                          Empi
                              RS Med
                              Zynex
                              EMSI
                      57%     Care Rehab
23%
                              Others




                                      17
Opportunities


•Sales channel expansion     •Sales channel expansion       •In development – non
(US & International)         (international distributors)   invasive blood volume
                                                            monitor
• New products introduced    •Existing electrotherapy
(NexWave & Iontophoresis,    technology base for            •Clinical trials commenced
InWave est. release 2012)    developing neuro
                             monitoring devices             •Large market/
•Large recurring revenue                                    International opportunities
stream                       •Large market/
                             International opportunities    •Evaluating
•Comprehensive billing and                                  complementary technology
reimbursement system         •Expanded product line         acquisitions
/process (all third party    (NeuroDynamix) through
payors, government,          acquisition (NeuroDyne         •Diversification of existing
workers compensation)        Medial)                        product line

                             •Diversification of existing
                             product line
                                                                                    18
Long-Term Goals

–   Listing on AMEX/NASDAQ
–   Develop devices and applications with high GPM
–   Continue to grow recurring revenue
–   Take only calculated risks
–   Continue net earnings growth plan
–   Positive free cash flow
–   Utilize a mix of acquisitions and organic based growth
    to drive valuation=stock price=private equity with low
    dilution and/or loan-based financing

                                                         19
Corporate & Ownership Structure




                Common Stock: 31,000,000 shares outstanding
•   Limited overhang, only 1,500,000 in employee stock options and 50,000
    warrants
•   Auditors: GHP Horwath, PC
•   Corporate Counsel: Perkins Coie
•   BOD: T. Simonton, M. Vitale, M. Wahlstrom, T. Sandgaard
                                                                            20
Management Team Bio
Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive Officer of Zynex, Inc. since
   founding the company in 1996. He has previously held management positions with companies such as ITT,
   Siemens, GN Danavox, Dataco and Philips. Most of his work has been in the areas of international sales and
   distribution, technology transfers, mergers and marketing management in the semiconductor, telecommunications,
   data communications and medical equipment industries. Mr. Sandgaard has a degree in electronics engineering
   from Denmark’s Odense University of Engineering and an MBA from Copenhagen Business School. Mr.
   Sandgaard has an in-depth knowledge of the industry and is the driving force as to the Company strategies.

Anthony Scalese has been Chief Financial Officer of Zynex, Inc. since September 2010. Mr. Scalese has over 15
    years of experience in accounting, finance and operations and has spent the past 13 years of his career in the
    high-tech and healthcare industries. His most recent position was Chief Financial Officer for Qualmark
    Corporation, in which he also served as President for various subsidiaries of Qualmark. He previously held
    positions at Coram Healthcare (now Apria Healthcare) as well as Foundation Health Systems (now Healthnet). Mr.
    Scalese is a Certified Public Accountant licensed in Colorado, received a Masters in Business Administration from
    the University of Colorado and a Bachelor of Science in Business Administration-Accounting from Colorado State
    University.

Robert "Bob" Cozart is the VP of Technical Operations who develops and manages all of the teams that make up the
    Purchasing, Production, Service, Warehouse, Facilities, and Shipping and Receiving departments. Mr. Cozart has
    over 26 years of management experience in electronics manufacturing, primarily with Class II and Class III
    medical devices with such companies as HEI, Colorado Medtech, Pfizer/Valleylab and Medtronic. Mr. Cozart holds
    an MBA from Creighton University in Omaha and a BS in Business from the University of Colorado in Boulder.

Keith White is the VP of Billing and Reimbursement responsible for all insurance billing and collection activities for the
     Zynex Medical division of Zynex. Mr. White has 30 years of experience in the medical industry, specifically
     focused on the, durable medical equipment, urinary incontinence, electrotherapy, and pain control / rehabilitation
     markets. He has an in-depth knowledge of the complex healthcare system and its reimbursement guidelines. Mr.
     White recently spent 20 years in various management positions with Empi, Inc., (now a division of DJO Global)
     including Director of Sales Operations and Patient Care Services. Mr. White holds a B.A. degree in Business
     Management, from Bethel University.


                                                                                                                         21
Management Team Bio (cont)
Robert Bird is the National Sales Manager responsible for all domestic sales within the rehabilitation and pain
    management markets and directs all domestic sales activities for the Zynex Medical division of Zynex. Mr. Bird has
    over 20 years of sales and management experience and holds a B.S. Degree in Business Administration from
    California State University, Hayward.

Lisa Magelby is the Sales Logistics Manager at Zynex Medical, Inc. Ms. Magelby has over 16 years of experience in
    the medical industry working in Home Health, Durable Medical Equipment, Respiratory Care, Pain Management,
    Medical Reimbursement and Regulatory Compliance. She previously held positions at Coram Healthcare (now
    Apria Healthcare) as well as Freedom Oxygen, A Walgreens Company (now Rotech). Ms. Magelby obtained a
    Bachelor’s degree from Texas State University with focus in Social Work and a Bachelor’s in Paralegal Studies
    from Kaplan University.

Dave Empey is the Director of Regulatory and Compliance for Zynex Inc. Mr. Empey has over 35 years of healthcare,
    clinical services, management, operations, medical equipment, accreditation, quality and compliance experience.
    Mr. Empey holds an MBA from the University of Denver and is a Registered Respiratory Therapist.

Victoria Cordova is the Director of Human Resources for Zynex Inc. Ms. Cordova has over 20 years of experience in
     all aspects of human resources, including previous positions with Evergreen Energy, US Foodservice, and
     Spectrum Laboratories. Ms. Cordova holds a Masters degree from the University of Phoenix and a Bachelor’s
     degree from the University of Phoenix in Business Management/Global Management.




                                                                                                                      22
Board of Director Bio
Mats Wahlström (independent) was appointed to the Board of Directors of Zynex, Inc in October 2010. Mr. Wahlström currently
     serves as Senior Advisor to the CEO and Chairman of Fresenius Medical Care, a renal care company. From January 2004
     through December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and from November
     2002 through December 2009 as President and CEO of Fresenius Medical Services, which operates more than 1,700
     dialysis clinics in the U.S. Mr. Wahlström has 25 years of experience in the healthcare field and 23 years of experience in the
     renal field. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including
     President and CEO of Gambro U.S. as well as CFO of the Gambro Group. Mr. Wahlström served as a director of Health
     Grades, Inc., a NASDAQ-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in
     October 2010.

Taylor Simonton (independent) was appointed to the Board of Directors of Zynex, Inc in October 2008 and serves as Chairman
     of the Audit Committee. Mr. Simonton is currently the Chairman of the Colorado chapter of the National Association of
     Corporate Directors (NACD), Chair of Audit Committee, Red Robin Gourmet Burgers, Inc. , Lead Director and Chair of the
     Audit Committee, Keating Capital, Inc., and serves on the Board of Managers, Quality Rail Services, LLC. Mr. Simonton
     retired in 2001 from a 35-year career with PricewaterhouseCoopers. While serving in the PricewaterhouseCoopers National
     office from 1998 - 2001, Taylor was a member of the Risk & Quality Group that handles all auditing and accounting
     standards, SEC, corporate governance, risk management and quality matters for the firm. He was one of six partners in a
     specialized SEC consulting group overseeing the quality of financial statements and SEC reporting for all
     PricewaterhouseCoopers foreign clients that publicly report in the U.S. Prior to that, Taylor participated in the firm's Partner
     International Program for three years, during which time he assisted Colombian companies in-country with capital-raising
     activities in the United States, consulted to major companies and coordinated IPO assistance, advised on due diligence and
     SEC regulatory matters and traveled extensively internationally assisting companies with SEC registration statements and
     other capital-raising activities. Since retiring, Taylor has served or is serving on a number of corporate boards of directors.
     He is a C.P.A. and holds a Certificate of Director Education from the Corporate Directors Institute. He received his B.S. in
     Accounting from the University of Tennessee.

Mary Beth Vitale (independent) was appointed to the Board of Directors of Zynex, Inc in October 2008 and serves on the Audit
    Committee. Ms. Vitale is currently the President of the Colorado chapter of the National Association of Corporate Directors
    (NACD), and Co-Founder of Pellera, LLC. Ms. Vitale is a general management executive with 25 years experience in the
    telecommunications and consumer products industries. Mary Beth was Chairman of the Board for Westwind Media, spent 5
    years on the Board of Intrado, sitting on the Audit, Compensation and Corporate Governance committees, and spent 3 years
    with RMI, sitting on the Audit Committee. Currently, Mary Beth is a member of the Board of Directors of CoBiz Financial
    Corp., and chairs the Audit Committee as a financial expert. She is also Lead Director and Finance Chair for Eye-Ris, a
    privately held software company, and is a member of their Compensation committee. She is a founding member of former
    Governor Owens Commission on Science and Technology and has been instrumental in forming its strategic direction over
    the past eight years. She was awarded her NACD Director Certificate in 2006, and has been a frequent speaker and
    presenter at many technology functions and seminars across the United States.

                                                                                                                                    23
Nov 2011   24
CONTACT INFO:
       For more information, please contact:

                 Anthony Scalese
          ascalese@zynexmed.com

                     Zynex, Inc.
             9990 Park Meadows Drive
               Lone Tree, CO 80124
Telephone: (303) 703-4906 Facsimile: (303) 347-9153
            www.zynexmed.com
                                                      25
Stock symbol:



ZYXI
                26

More Related Content

What's hot

coventry health care annual reports2003
coventry health care annual reports2003 coventry health care annual reports2003
coventry health care annual reports2003
finance27
 
Bank of india ru2 qfy2011-221010
Bank of india ru2 qfy2011-221010Bank of india ru2 qfy2011-221010
Bank of india ru2 qfy2011-221010
Angel Broking
 
Nordnet Q2 2011 report
Nordnet Q2 2011 reportNordnet Q2 2011 report
Nordnet Q2 2011 report
Nordnet
 
wyeth 2006 Annual Review
wyeth 2006 Annual Reviewwyeth 2006 Annual Review
wyeth 2006 Annual Review
finance12
 
Sonoco 2Q 2012 Results Presentation
Sonoco 2Q 2012 Results PresentationSonoco 2Q 2012 Results Presentation
Sonoco 2Q 2012 Results Presentation
Sonoco
 
Venture Capitalist competition Analysis Team Lollapalooza
Venture Capitalist competition Analysis Team LollapaloozaVenture Capitalist competition Analysis Team Lollapalooza
Venture Capitalist competition Analysis Team Lollapalooza
doshihardik
 
Bloomsbury integrated assurance chapter (4)
Bloomsbury integrated assurance chapter (4)Bloomsbury integrated assurance chapter (4)
Bloomsbury integrated assurance chapter (4)
Workiva
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
Profarma
 
Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711
Angel Broking
 
1Q11 Presentation
1Q11 Presentation1Q11 Presentation
1Q11 Presentation
Paraná Banco
 
4Q12 Presentation
4Q12 Presentation4Q12 Presentation
4Q12 Presentation
Arteris S.A.
 
1Q07 Results
1Q07 Results1Q07 Results
alltel 4q05supplement
alltel  4q05supplementalltel  4q05supplement
alltel 4q05supplement
finance27
 
Second Quarter 2007 Earnings Presentation
Second Quarter 2007 Earnings PresentationSecond Quarter 2007 Earnings Presentation
Second Quarter 2007 Earnings Presentation
QuarterlyEarningsReports3
 
Honeywell Q2 2006 Earnings Conference Call Presentation
Honeywell Q2 2006 Earnings Conference Call PresentationHoneywell Q2 2006 Earnings Conference Call Presentation
Honeywell Q2 2006 Earnings Conference Call Presentation
finance8
 
Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011
Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011
Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011
Deutsche EuroShop AG
 
Microsoft Company
Microsoft CompanyMicrosoft Company
Microsoft Company
dgalperin2010
 
Bank of baroda_q4_fy10
Bank of baroda_q4_fy10Bank of baroda_q4_fy10
Bank of baroda_q4_fy10
mittalmanisha
 
Daily Newsletter: 28th December, 2010
Daily Newsletter: 28th December, 2010Daily Newsletter: 28th December, 2010
Daily Newsletter: 28th December, 2010
Fullerton Securities
 

What's hot (19)

coventry health care annual reports2003
coventry health care annual reports2003 coventry health care annual reports2003
coventry health care annual reports2003
 
Bank of india ru2 qfy2011-221010
Bank of india ru2 qfy2011-221010Bank of india ru2 qfy2011-221010
Bank of india ru2 qfy2011-221010
 
Nordnet Q2 2011 report
Nordnet Q2 2011 reportNordnet Q2 2011 report
Nordnet Q2 2011 report
 
wyeth 2006 Annual Review
wyeth 2006 Annual Reviewwyeth 2006 Annual Review
wyeth 2006 Annual Review
 
Sonoco 2Q 2012 Results Presentation
Sonoco 2Q 2012 Results PresentationSonoco 2Q 2012 Results Presentation
Sonoco 2Q 2012 Results Presentation
 
Venture Capitalist competition Analysis Team Lollapalooza
Venture Capitalist competition Analysis Team LollapaloozaVenture Capitalist competition Analysis Team Lollapalooza
Venture Capitalist competition Analysis Team Lollapalooza
 
Bloomsbury integrated assurance chapter (4)
Bloomsbury integrated assurance chapter (4)Bloomsbury integrated assurance chapter (4)
Bloomsbury integrated assurance chapter (4)
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
 
Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711Mining%20bill %20 impact%20analysis-eu-080711
Mining%20bill %20 impact%20analysis-eu-080711
 
1Q11 Presentation
1Q11 Presentation1Q11 Presentation
1Q11 Presentation
 
4Q12 Presentation
4Q12 Presentation4Q12 Presentation
4Q12 Presentation
 
1Q07 Results
1Q07 Results1Q07 Results
1Q07 Results
 
alltel 4q05supplement
alltel  4q05supplementalltel  4q05supplement
alltel 4q05supplement
 
Second Quarter 2007 Earnings Presentation
Second Quarter 2007 Earnings PresentationSecond Quarter 2007 Earnings Presentation
Second Quarter 2007 Earnings Presentation
 
Honeywell Q2 2006 Earnings Conference Call Presentation
Honeywell Q2 2006 Earnings Conference Call PresentationHoneywell Q2 2006 Earnings Conference Call Presentation
Honeywell Q2 2006 Earnings Conference Call Presentation
 
Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011
Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011
Deutsche EuroShop - Conference Call Presentation - Interim Report H1 2011
 
Microsoft Company
Microsoft CompanyMicrosoft Company
Microsoft Company
 
Bank of baroda_q4_fy10
Bank of baroda_q4_fy10Bank of baroda_q4_fy10
Bank of baroda_q4_fy10
 
Daily Newsletter: 28th December, 2010
Daily Newsletter: 28th December, 2010Daily Newsletter: 28th December, 2010
Daily Newsletter: 28th December, 2010
 

Viewers also liked

Sophie Krotoff portfolio
Sophie Krotoff portfolioSophie Krotoff portfolio
Sophie Krotoff portfolio
Sophie Krotoff
 
EUDEM Master I.B.A. Santander
EUDEM Master I.B.A. SantanderEUDEM Master I.B.A. Santander
EUDEM Master I.B.A. Santander
NABEGA
 
Seminari Formació Bonificada
Seminari Formació BonificadaSeminari Formació Bonificada
Seminari Formació Bonificadacempreses1988
 
Suits for Success 2016 Report
 Suits for Success 2016 Report Suits for Success 2016 Report
Suits for Success 2016 Report
Chow Nga Sze Jennifer
 
Ici final report
Ici final reportIci final report
Ici final report
Devin Wong
 
Giới thiệu công ty TNHH Minh Nam
Giới thiệu công ty TNHH Minh NamGiới thiệu công ty TNHH Minh Nam
Giới thiệu công ty TNHH Minh Nam
khoanguyenkind
 
e-Portafolio
e-Portafolioe-Portafolio
e-Portafolio
David Clavijo
 
Charla SaludOral
Charla SaludOral Charla SaludOral
Charla SaludOral
Clínica Dental Pradillo
 
Projeto Remessas
Projeto RemessasProjeto Remessas
El mundo se acaba 2
El mundo se acaba 2El mundo se acaba 2
El mundo se acaba 2
oscar alejandro
 
Web'11 press kit
Web'11 press kitWeb'11 press kit
Web'11 press kit
Orange Dev
 
Generos periodisticos
Generos periodisticosGeneros periodisticos
Generos periodisticos
saul silvano ventura martinez
 
Tú eres lo que estás buscando (en situaciones de discapacidad).
Tú eres lo que estás buscando (en situaciones de discapacidad).Tú eres lo que estás buscando (en situaciones de discapacidad).
Tú eres lo que estás buscando (en situaciones de discapacidad).
José María
 
Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...
Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...
Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...
Academia de Ingeniería de México
 
Web design for journalists
Web design for journalistsWeb design for journalists
Web design for journalists
CubReporters.org
 
MASTER SPAS TWILIGHT OWNER’S MANUAL
MASTER SPAS TWILIGHT OWNER’S MANUALMASTER SPAS TWILIGHT OWNER’S MANUAL
MASTER SPAS TWILIGHT OWNER’S MANUAL
Master Spa Parts
 
Tecnocreatividad
TecnocreatividadTecnocreatividad
Tecnocreatividad
Bots2h
 
Concurso traslado 2015
Concurso traslado 2015Concurso traslado 2015
Concurso traslado 2015
Cgt Sevilla
 
Los virus odb
Los  virus odbLos  virus odb
Los virus odb
Andrea Soto
 

Viewers also liked (20)

Sophie Krotoff portfolio
Sophie Krotoff portfolioSophie Krotoff portfolio
Sophie Krotoff portfolio
 
EUDEM Master I.B.A. Santander
EUDEM Master I.B.A. SantanderEUDEM Master I.B.A. Santander
EUDEM Master I.B.A. Santander
 
Seminari Formació Bonificada
Seminari Formació BonificadaSeminari Formació Bonificada
Seminari Formació Bonificada
 
Suits for Success 2016 Report
 Suits for Success 2016 Report Suits for Success 2016 Report
Suits for Success 2016 Report
 
Ici final report
Ici final reportIci final report
Ici final report
 
Giới thiệu công ty TNHH Minh Nam
Giới thiệu công ty TNHH Minh NamGiới thiệu công ty TNHH Minh Nam
Giới thiệu công ty TNHH Minh Nam
 
e-Portafolio
e-Portafolioe-Portafolio
e-Portafolio
 
Charla SaludOral
Charla SaludOral Charla SaludOral
Charla SaludOral
 
Projeto Remessas
Projeto RemessasProjeto Remessas
Projeto Remessas
 
El mundo se acaba 2
El mundo se acaba 2El mundo se acaba 2
El mundo se acaba 2
 
Web'11 press kit
Web'11 press kitWeb'11 press kit
Web'11 press kit
 
Generos periodisticos
Generos periodisticosGeneros periodisticos
Generos periodisticos
 
Fire fans
Fire fansFire fans
Fire fans
 
Tú eres lo que estás buscando (en situaciones de discapacidad).
Tú eres lo que estás buscando (en situaciones de discapacidad).Tú eres lo que estás buscando (en situaciones de discapacidad).
Tú eres lo que estás buscando (en situaciones de discapacidad).
 
Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...
Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...
Aspectos relevantes en el desarrollo de catalizadores para la eliminación de ...
 
Web design for journalists
Web design for journalistsWeb design for journalists
Web design for journalists
 
MASTER SPAS TWILIGHT OWNER’S MANUAL
MASTER SPAS TWILIGHT OWNER’S MANUALMASTER SPAS TWILIGHT OWNER’S MANUAL
MASTER SPAS TWILIGHT OWNER’S MANUAL
 
Tecnocreatividad
TecnocreatividadTecnocreatividad
Tecnocreatividad
 
Concurso traslado 2015
Concurso traslado 2015Concurso traslado 2015
Concurso traslado 2015
 
Los virus odb
Los  virus odbLos  virus odb
Los virus odb
 

Similar to Zyxi ppt (july 2012)

Zynex December 2013 Investor Presentation
Zynex December 2013 Investor PresentationZynex December 2013 Investor Presentation
Zynex December 2013 Investor Presentation
issuerdirect
 
December 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor PresentationDecember 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor Presentation
Pritesh Patel
 
July 2016 Zynex Investor Presentation
July 2016 Zynex Investor PresentationJuly 2016 Zynex Investor Presentation
July 2016 Zynex Investor Presentation
Martin Sandgaard
 
Angle interim results 2012 26jan12
Angle interim results 2012 26jan12Angle interim results 2012 26jan12
Angle interim results 2012 26jan12
ANGLE plc
 
Immunotec Press Release Q4 2008
Immunotec  Press Release  Q4 2008Immunotec  Press Release  Q4 2008
Immunotec Press Release Q4 2008
Avis Betancourt
 
Nordnet Q1 2011 report
Nordnet Q1 2011 reportNordnet Q1 2011 report
Nordnet Q1 2011 report
Nordnet
 
danaher 08_3Q_Release
danaher 08_3Q_Releasedanaher 08_3Q_Release
danaher 08_3Q_Release
finance24
 
Accounting for build environment
Accounting for build environmentAccounting for build environment
Accounting for build environment
EVERSENDAI ENGINEERING (L.L.C.)
 
Resultados bayer
Resultados bayerResultados bayer
nationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplementnationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplement
finance11
 
danaher 01-2qrel
danaher 01-2qreldanaher 01-2qrel
danaher 01-2qrel
finance24
 
danaher 06_4Q_Release
danaher 06_4Q_Releasedanaher 06_4Q_Release
danaher 06_4Q_Release
finance24
 
Humc Financials 20090001
Humc Financials 20090001Humc Financials 20090001
Humc Financials 20090001
Hoboken Resistance
 
Nordnet Q3 2011 report
Nordnet Q3 2011 reportNordnet Q3 2011 report
Nordnet Q3 2011 report
Nordnet
 
credit suisse Quarterly Report Q3/2004
credit suisse  Quarterly Report Q3/2004credit suisse  Quarterly Report Q3/2004
credit suisse Quarterly Report Q3/2004
QuarterlyEarningsReports2
 
danaher 07_4Q_Release
danaher 07_4Q_Releasedanaher 07_4Q_Release
danaher 07_4Q_Release
finance24
 
danaher 04-2Q-REL
danaher 04-2Q-RELdanaher 04-2Q-REL
danaher 04-2Q-REL
finance24
 
1Q08 Presentation
1Q08 Presentation1Q08 Presentation
1Q08 Presentation
Paraná Banco
 
Q2 2012 Investor Conference Call Presentation
Q2 2012 Investor Conference Call PresentationQ2 2012 Investor Conference Call Presentation
Q2 2012 Investor Conference Call Presentation
Bayer
 
danaher 05-2q-rel
danaher 05-2q-reldanaher 05-2q-rel
danaher 05-2q-rel
finance24
 

Similar to Zyxi ppt (july 2012) (20)

Zynex December 2013 Investor Presentation
Zynex December 2013 Investor PresentationZynex December 2013 Investor Presentation
Zynex December 2013 Investor Presentation
 
December 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor PresentationDecember 2015 ZYXI Investor Presentation
December 2015 ZYXI Investor Presentation
 
July 2016 Zynex Investor Presentation
July 2016 Zynex Investor PresentationJuly 2016 Zynex Investor Presentation
July 2016 Zynex Investor Presentation
 
Angle interim results 2012 26jan12
Angle interim results 2012 26jan12Angle interim results 2012 26jan12
Angle interim results 2012 26jan12
 
Immunotec Press Release Q4 2008
Immunotec  Press Release  Q4 2008Immunotec  Press Release  Q4 2008
Immunotec Press Release Q4 2008
 
Nordnet Q1 2011 report
Nordnet Q1 2011 reportNordnet Q1 2011 report
Nordnet Q1 2011 report
 
danaher 08_3Q_Release
danaher 08_3Q_Releasedanaher 08_3Q_Release
danaher 08_3Q_Release
 
Accounting for build environment
Accounting for build environmentAccounting for build environment
Accounting for build environment
 
Resultados bayer
Resultados bayerResultados bayer
Resultados bayer
 
nationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplementnationwide 2Q07 Statistical Supplement
nationwide 2Q07 Statistical Supplement
 
danaher 01-2qrel
danaher 01-2qreldanaher 01-2qrel
danaher 01-2qrel
 
danaher 06_4Q_Release
danaher 06_4Q_Releasedanaher 06_4Q_Release
danaher 06_4Q_Release
 
Humc Financials 20090001
Humc Financials 20090001Humc Financials 20090001
Humc Financials 20090001
 
Nordnet Q3 2011 report
Nordnet Q3 2011 reportNordnet Q3 2011 report
Nordnet Q3 2011 report
 
credit suisse Quarterly Report Q3/2004
credit suisse  Quarterly Report Q3/2004credit suisse  Quarterly Report Q3/2004
credit suisse Quarterly Report Q3/2004
 
danaher 07_4Q_Release
danaher 07_4Q_Releasedanaher 07_4Q_Release
danaher 07_4Q_Release
 
danaher 04-2Q-REL
danaher 04-2Q-RELdanaher 04-2Q-REL
danaher 04-2Q-REL
 
1Q08 Presentation
1Q08 Presentation1Q08 Presentation
1Q08 Presentation
 
Q2 2012 Investor Conference Call Presentation
Q2 2012 Investor Conference Call PresentationQ2 2012 Investor Conference Call Presentation
Q2 2012 Investor Conference Call Presentation
 
danaher 05-2q-rel
danaher 05-2q-reldanaher 05-2q-rel
danaher 05-2q-rel
 

More from Company Spotlight

Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 YearsPresentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Company Spotlight
 
Aben resources presentation
Aben resources presentationAben resources presentation
Aben resources presentation
Company Spotlight
 
Aben Resources Ltd.
Aben Resources Ltd.Aben Resources Ltd.
Aben Resources Ltd.
Company Spotlight
 
Cypress Development Corp. Investor Presentation
Cypress Development Corp. Investor PresentationCypress Development Corp. Investor Presentation
Cypress Development Corp. Investor Presentation
Company Spotlight
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
Company Spotlight
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
Company Spotlight
 
Aben Resources Ltd.
Aben Resources Ltd.Aben Resources Ltd.
Aben Resources Ltd.
Company Spotlight
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
Company Spotlight
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. Presentation
Company Spotlight
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
Company Spotlight
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
Company Spotlight
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. Presentation
Company Spotlight
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
Company Spotlight
 
TerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate PresentationTerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate Presentation
Company Spotlight
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
Company Spotlight
 
Cypress Development Corp
Cypress Development CorpCypress Development Corp
Cypress Development Corp
Company Spotlight
 
TerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate PresentationTerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate Presentation
Company Spotlight
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
Company Spotlight
 
Cypress Development Corp
Cypress Development CorpCypress Development Corp
Cypress Development Corp
Company Spotlight
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
Company Spotlight
 

More from Company Spotlight (20)

Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 YearsPresentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 Years
 
Aben resources presentation
Aben resources presentationAben resources presentation
Aben resources presentation
 
Aben Resources Ltd.
Aben Resources Ltd.Aben Resources Ltd.
Aben Resources Ltd.
 
Cypress Development Corp. Investor Presentation
Cypress Development Corp. Investor PresentationCypress Development Corp. Investor Presentation
Cypress Development Corp. Investor Presentation
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
 
Aben Resources Ltd.
Aben Resources Ltd.Aben Resources Ltd.
Aben Resources Ltd.
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. Presentation
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
 
Aben Resources Ltd. Presentation
Aben Resources Ltd. PresentationAben Resources Ltd. Presentation
Aben Resources Ltd. Presentation
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
 
TerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate PresentationTerraX Minerals - Corporate Presentation
TerraX Minerals - Corporate Presentation
 
Aben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate PresentationAben Resources Ltd. Corporate Presentation
Aben Resources Ltd. Corporate Presentation
 
Cypress Development Corp
Cypress Development CorpCypress Development Corp
Cypress Development Corp
 
TerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate PresentationTerraX Minerals, Inc. Corporate Presentation
TerraX Minerals, Inc. Corporate Presentation
 
Cypress Development Corp. Presentation
Cypress Development Corp. PresentationCypress Development Corp. Presentation
Cypress Development Corp. Presentation
 
Cypress Development Corp
Cypress Development CorpCypress Development Corp
Cypress Development Corp
 
Cypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate PresentationCypress Development Corp. Corporate Presentation
Cypress Development Corp. Corporate Presentation
 

Recently uploaded

Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fixKalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
satta Matta matka 143 Kalyan chart jodi 6366249026
 
Cover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SUCover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SU
msthrill
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
CIOWomenMagazine
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Science Around Us Module 2 Matter Around Us
Science Around Us Module 2 Matter Around UsScience Around Us Module 2 Matter Around Us
Science Around Us Module 2 Matter Around Us
PennapaKeavsiri
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
dazzjoker
 
Kirill Klip GEM Royalty TNR Gold Copper Presentation
Kirill Klip GEM Royalty TNR Gold Copper PresentationKirill Klip GEM Royalty TNR Gold Copper Presentation
Kirill Klip GEM Royalty TNR Gold Copper Presentation
Kirill Klip
 
Enhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: IntroductionEnhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: Introduction
Cor Verdouw
 
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Kirill Klip GEM Royalty TNR Gold Lithium PresentationKirill Klip GEM Royalty TNR Gold Lithium Presentation
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Kirill Klip
 
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian MatkaDpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
irhcs
 
Pro Tips for Effortless Contract Management
Pro Tips for Effortless Contract ManagementPro Tips for Effortless Contract Management
Pro Tips for Effortless Contract Management
Eternity Paralegal Services
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
my Pandit
 
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
Ksquare Energy Pvt. Ltd.
 
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
taqyea
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
essorprof62
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
thesiliconleaders
 

Recently uploaded (20)

Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fixKalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
 
Cover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SUCover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SU
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Science Around Us Module 2 Matter Around Us
Science Around Us Module 2 Matter Around UsScience Around Us Module 2 Matter Around Us
Science Around Us Module 2 Matter Around Us
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
 
Kirill Klip GEM Royalty TNR Gold Copper Presentation
Kirill Klip GEM Royalty TNR Gold Copper PresentationKirill Klip GEM Royalty TNR Gold Copper Presentation
Kirill Klip GEM Royalty TNR Gold Copper Presentation
 
Enhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: IntroductionEnhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: Introduction
 
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Kirill Klip GEM Royalty TNR Gold Lithium PresentationKirill Klip GEM Royalty TNR Gold Lithium Presentation
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
 
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian MatkaDpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
 
Pro Tips for Effortless Contract Management
Pro Tips for Effortless Contract ManagementPro Tips for Effortless Contract Management
Pro Tips for Effortless Contract Management
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
 
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
 
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
 

Zyxi ppt (july 2012)

  • 1. 1
  • 2. Forward Looking Statements Statements made in this presentation include financial estimates and forward-looking statements that are not historical facts. Each of these estimates and forward-looking statements involves risk and uncertainties. These estimates are based on present circumstances, information currently available, and assumptions about future revenues, industry growth, and general economic conditions. Estimates are inherently uncertain as they are based on assumptions concerning future events. No representations can be made as to the accuracy of such information or the reliability of such assumptions. Accordingly, actual revenues and expenditures may vary significantly from the Company’s estimates, and actual results or developments may differ materially from those expressed or implied by the forward-looking statements. Factors that could cause actual results to differ from the financial estimates and forward-looking statements in this presentation include those described in the Company’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Therefore, neither the Company’s estimates nor the assumptions upon which they are based are to be interpreted as a guarantee or promise of the Company or management. The Company has no obligation to modify, amend, update, alter, or change the estimates contained herein. The Company released its financial results for the year ended December 31, 2011 and first quarter ended 2012. The Company’s 2012 revenue and EPS guidance is valid only as of the date it was given and is not being updated or reaffirmed herein. For more information, please contact: Anthony Scalese ascalese@zynexmed.com Zynex, Inc. 9990 Park Meadows Drive Lone Tree, CO 80124 Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynexmed.com 2
  • 3. Zynex Overview • Develops, manufactures and markets non-invasive FDA-CE marked medical devices for pain relief, stroke/spinal cord rehabilitation, neurological and cardiac monitoring • Publicly Traded OTCBB: ZYXI • In operation since 1996 • Headquartered in Lone Tree, Colorado • High revenue growth >50% CAGR since 1996 (2012 est. Revenue $40 million) • Profitable ($0.05 EPS 2011, $0.06-$0.08 EPS est. 2012) • $4B+ potential market • Ranked fastest growing medical equipment company in Rocky Mountain region and 9th fastest growing medical equipment company in US and Canada (Deloitte Fast 500) ZYNEX MEDICAL (ZMI): • >70%+ recurring revenue with more than 40,000 units in the field • High GPM of >75% • Helped over 150,000 patients since inception ZYNEX NEURODIAGNOSTICS (ZND): • Proprietary products (NeuroMove, NeuroDynamix-product line recently acquired) ZYNEX MONITORING SOLUTIONS (ZMS): • Development of proprietary non-invasive blood volume monitor 3
  • 4. Revenue Growth >50% CAGR * 2012 estimated revenue based on guidance previously provided 4
  • 5. Financial Summary Annual Financial Data 2011 2010 2009 2008 2007 2006 (000’s) Net Revenue $34,148 $24,085 $18,681 $11,764 $8,048 $2,557 Gross Profit 26,777 18,883 14,888 9,524 7,319 2,253 Net Income (loss) 1,564 350 2,382 111 2,131 (320) EPS 0.05 0.01 0.08 0.00 0.07 (0.01) Cash 789 602 863 - - 265 Total Stock Holders 10,139 8,182 7,486 4,774 3,618 1,287 Equity Common Shares 31,000 30,600 30,500 29,900 26,800 26,300 Outstanding 5
  • 6. Financial Summary Balance Sheet Mar-12 Dec-11 Dec-10 Cash 742 789 602 A/R 11,642 10,984 7,309 Inventory 5,580 4,557 3,641 Other Assets 1,691 1,718 980 Current Assets 19,655 18,048 12,532 PP&E 3,446 3,422 2,906 Other Assets 787 315 263 TOTAL ASSETS 23,888 $21,785 $15,701 Line of Credit 4,385 3,290 1,270 Other Liabilities 6,937 6,460 4,282 Current Liabilities 11,322 9,750 5,552 Other Liabilities 1,902 1,896 1,967 Total Liabilities 13,224 11,646 7,519 Common Stock 31 31 31 Paid-in-capital 5,300 5,095 4,702 Retained Earnings 5,333 5,013 3,449 Total Stockholders' Equity 10,664 10,139 8,182 Total Liab. And S.Equity 23,888 $21,785 $15,701
  • 7. Business Structure ZYNEX, INC. Current Revenue Driver ~1% of Net Revenue R&D ZYNEX ZYNEX ZYNEX NEURODIAGNOSTICS MONITORING MEDICAL INC. INC. SOLUTIONS INC. International Conduit for all Subs ZYNEX EUROPE ApS 7
  • 8. History 1996 Founded by Thomas Sandgaard 1999 First Zynex-manufactured device cleared by FDA 2001 Shifted from wholesale-only to direct sales to physicians and Patients 2003 FDA clearance for full line of Electrotherapy Devices and NeuroMove stroke-rehab device 2004 Reverse Merger into a Public shell 2008 Receives European CE Mark on Key Products Opens new 75,000 sq. ft. distribution and headquarters building 2010 Establishes 2 new subsidiaries Added industry expert to Board Commenced clinical evaluations for blood volume monitor medical device. 2011 Added Iontophoresis to product line Received 510k clearance for next generation TENS device Ramped up Zynex Medical sales force Completed asset acquisition of NeuroDyne, through Zynex NeuroDiagnostics Sub 2012 Established European subsidiary, Zynex Europe Submission to FDA for InWave device (incontinence treatment) 8
  • 9. Available Market TAM ~ 4.0B Zynex Medical ~$550M Electrotherapy Devices Zynex Monitoring Solutions ~$3B Cardiac Monitoring Devices Zynex NeuroDiagnostic ~$900M Neurological Diagnosis Devices 9
  • 10. Products •Complete line of electrotherapy pain management devices-FDA and EU cleared •Augments healing, alleviates swelling through increased blood circulation, NexWave and reduces both acute/chronic pain through the use of electrical currents TruWave+ •Consumables required E-Wave •Require a prescription IF8000 •Reimbursed by health insurance IF8100 (including Medicare/Medicaid) Iontophoresis •May be rented or purchased InWave (est. 2012) Consumables (battery/electrode) 10
  • 11. Products •Stroke/spinal cord rehabilitation devices-FDA and EU cleared •Augment healing, as well as assist in recovery for stroke, Spinal Cord Injuries and Traumatic Brain Injury, retrains muscles, increases range of motion NeuroMove •Consumables required Consumables (battery/electrode) Sensors Other – acquisition/R&D 11
  • 12. Products •Acquisition Mar 2012 (NeuroDyne Medical)- •Non-invasive measurement devices for surface electromyography (“sEMG”) and autonomic nervous systems, used for evaluation and treatment of neurological and neuromuscular disorders as well as education and research. •Medial sensors required NeuroDynamix (acquired products) Sensors Other – acquisition/R&D 12
  • 13. Products •In development – non invasive blood volume monitor •Used in operating and recovery rooms to detect blood loss and internal bleeding •Clinical trials commenced •Patent filed Blood Volume Monitor (in development) Other – acquisition/R&D 13
  • 14. Zynex Medical-Existing Business Zynex-focus on Continued geographic customer service expansion for growth Sales Representative Doctor More units in Zynex-proven Zynex Patient field = greater system/process recurring revenue Insurance Company Sales Representative Barrier to entry for most Zynex 14
  • 15. Competitive Advantage Comprehensive Billing and Unique Technology Unique Technology Reimbursement System NeuroMove medical device has Blood Volume Monitor (in process) is Accept and bill virtually all insurance unique technology for stroke anticipated to meet current unmet plans, including Medicare rehabilitation (little to no competition) needs in a significant cardiac monitoring market (little to no competition) Breadth of Product offering Breadth of Product offering Range of products enables Newly acquired Neurodynamix physicians and rehab facilities with a systems offer a complete suite of full suite of products for their diagnostics software to serve market patients needs in a singular/modular format (same hardware) Customer Service Customer Service Superior post sale “hands on” patient support for device education Superior post sale “hands on” and proper fitting – “Happy patient = patient support for device education Happy doctor” Distribution Channels Over 200 sales reps/fitters domestically 15
  • 16. Opportunities •Sales channel expansion (US & International) • New products introduced (NexWave & Iontophoresis, InWave est. release 2012) •Large recurring revenue stream •Comprehensive billing and reimbursement system /process (all third party payors, government, workers compensation) 16
  • 17. Zynex Medical-Opportunities 3% 1% 6% 10% Empi RS Med Zynex EMSI 57% Care Rehab 23% Others 17
  • 18. Opportunities •Sales channel expansion •Sales channel expansion •In development – non (US & International) (international distributors) invasive blood volume monitor • New products introduced •Existing electrotherapy (NexWave & Iontophoresis, technology base for •Clinical trials commenced InWave est. release 2012) developing neuro monitoring devices •Large market/ •Large recurring revenue International opportunities stream •Large market/ International opportunities •Evaluating •Comprehensive billing and complementary technology reimbursement system •Expanded product line acquisitions /process (all third party (NeuroDynamix) through payors, government, acquisition (NeuroDyne •Diversification of existing workers compensation) Medial) product line •Diversification of existing product line 18
  • 19. Long-Term Goals – Listing on AMEX/NASDAQ – Develop devices and applications with high GPM – Continue to grow recurring revenue – Take only calculated risks – Continue net earnings growth plan – Positive free cash flow – Utilize a mix of acquisitions and organic based growth to drive valuation=stock price=private equity with low dilution and/or loan-based financing 19
  • 20. Corporate & Ownership Structure Common Stock: 31,000,000 shares outstanding • Limited overhang, only 1,500,000 in employee stock options and 50,000 warrants • Auditors: GHP Horwath, PC • Corporate Counsel: Perkins Coie • BOD: T. Simonton, M. Vitale, M. Wahlstrom, T. Sandgaard 20
  • 21. Management Team Bio Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive Officer of Zynex, Inc. since founding the company in 1996. He has previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco and Philips. Most of his work has been in the areas of international sales and distribution, technology transfers, mergers and marketing management in the semiconductor, telecommunications, data communications and medical equipment industries. Mr. Sandgaard has a degree in electronics engineering from Denmark’s Odense University of Engineering and an MBA from Copenhagen Business School. Mr. Sandgaard has an in-depth knowledge of the industry and is the driving force as to the Company strategies. Anthony Scalese has been Chief Financial Officer of Zynex, Inc. since September 2010. Mr. Scalese has over 15 years of experience in accounting, finance and operations and has spent the past 13 years of his career in the high-tech and healthcare industries. His most recent position was Chief Financial Officer for Qualmark Corporation, in which he also served as President for various subsidiaries of Qualmark. He previously held positions at Coram Healthcare (now Apria Healthcare) as well as Foundation Health Systems (now Healthnet). Mr. Scalese is a Certified Public Accountant licensed in Colorado, received a Masters in Business Administration from the University of Colorado and a Bachelor of Science in Business Administration-Accounting from Colorado State University. Robert "Bob" Cozart is the VP of Technical Operations who develops and manages all of the teams that make up the Purchasing, Production, Service, Warehouse, Facilities, and Shipping and Receiving departments. Mr. Cozart has over 26 years of management experience in electronics manufacturing, primarily with Class II and Class III medical devices with such companies as HEI, Colorado Medtech, Pfizer/Valleylab and Medtronic. Mr. Cozart holds an MBA from Creighton University in Omaha and a BS in Business from the University of Colorado in Boulder. Keith White is the VP of Billing and Reimbursement responsible for all insurance billing and collection activities for the Zynex Medical division of Zynex. Mr. White has 30 years of experience in the medical industry, specifically focused on the, durable medical equipment, urinary incontinence, electrotherapy, and pain control / rehabilitation markets. He has an in-depth knowledge of the complex healthcare system and its reimbursement guidelines. Mr. White recently spent 20 years in various management positions with Empi, Inc., (now a division of DJO Global) including Director of Sales Operations and Patient Care Services. Mr. White holds a B.A. degree in Business Management, from Bethel University. 21
  • 22. Management Team Bio (cont) Robert Bird is the National Sales Manager responsible for all domestic sales within the rehabilitation and pain management markets and directs all domestic sales activities for the Zynex Medical division of Zynex. Mr. Bird has over 20 years of sales and management experience and holds a B.S. Degree in Business Administration from California State University, Hayward. Lisa Magelby is the Sales Logistics Manager at Zynex Medical, Inc. Ms. Magelby has over 16 years of experience in the medical industry working in Home Health, Durable Medical Equipment, Respiratory Care, Pain Management, Medical Reimbursement and Regulatory Compliance. She previously held positions at Coram Healthcare (now Apria Healthcare) as well as Freedom Oxygen, A Walgreens Company (now Rotech). Ms. Magelby obtained a Bachelor’s degree from Texas State University with focus in Social Work and a Bachelor’s in Paralegal Studies from Kaplan University. Dave Empey is the Director of Regulatory and Compliance for Zynex Inc. Mr. Empey has over 35 years of healthcare, clinical services, management, operations, medical equipment, accreditation, quality and compliance experience. Mr. Empey holds an MBA from the University of Denver and is a Registered Respiratory Therapist. Victoria Cordova is the Director of Human Resources for Zynex Inc. Ms. Cordova has over 20 years of experience in all aspects of human resources, including previous positions with Evergreen Energy, US Foodservice, and Spectrum Laboratories. Ms. Cordova holds a Masters degree from the University of Phoenix and a Bachelor’s degree from the University of Phoenix in Business Management/Global Management. 22
  • 23. Board of Director Bio Mats Wahlström (independent) was appointed to the Board of Directors of Zynex, Inc in October 2010. Mr. Wahlström currently serves as Senior Advisor to the CEO and Chairman of Fresenius Medical Care, a renal care company. From January 2004 through December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, which operates more than 1,700 dialysis clinics in the U.S. Mr. Wahlström has 25 years of experience in the healthcare field and 23 years of experience in the renal field. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including President and CEO of Gambro U.S. as well as CFO of the Gambro Group. Mr. Wahlström served as a director of Health Grades, Inc., a NASDAQ-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010. Taylor Simonton (independent) was appointed to the Board of Directors of Zynex, Inc in October 2008 and serves as Chairman of the Audit Committee. Mr. Simonton is currently the Chairman of the Colorado chapter of the National Association of Corporate Directors (NACD), Chair of Audit Committee, Red Robin Gourmet Burgers, Inc. , Lead Director and Chair of the Audit Committee, Keating Capital, Inc., and serves on the Board of Managers, Quality Rail Services, LLC. Mr. Simonton retired in 2001 from a 35-year career with PricewaterhouseCoopers. While serving in the PricewaterhouseCoopers National office from 1998 - 2001, Taylor was a member of the Risk & Quality Group that handles all auditing and accounting standards, SEC, corporate governance, risk management and quality matters for the firm. He was one of six partners in a specialized SEC consulting group overseeing the quality of financial statements and SEC reporting for all PricewaterhouseCoopers foreign clients that publicly report in the U.S. Prior to that, Taylor participated in the firm's Partner International Program for three years, during which time he assisted Colombian companies in-country with capital-raising activities in the United States, consulted to major companies and coordinated IPO assistance, advised on due diligence and SEC regulatory matters and traveled extensively internationally assisting companies with SEC registration statements and other capital-raising activities. Since retiring, Taylor has served or is serving on a number of corporate boards of directors. He is a C.P.A. and holds a Certificate of Director Education from the Corporate Directors Institute. He received his B.S. in Accounting from the University of Tennessee. Mary Beth Vitale (independent) was appointed to the Board of Directors of Zynex, Inc in October 2008 and serves on the Audit Committee. Ms. Vitale is currently the President of the Colorado chapter of the National Association of Corporate Directors (NACD), and Co-Founder of Pellera, LLC. Ms. Vitale is a general management executive with 25 years experience in the telecommunications and consumer products industries. Mary Beth was Chairman of the Board for Westwind Media, spent 5 years on the Board of Intrado, sitting on the Audit, Compensation and Corporate Governance committees, and spent 3 years with RMI, sitting on the Audit Committee. Currently, Mary Beth is a member of the Board of Directors of CoBiz Financial Corp., and chairs the Audit Committee as a financial expert. She is also Lead Director and Finance Chair for Eye-Ris, a privately held software company, and is a member of their Compensation committee. She is a founding member of former Governor Owens Commission on Science and Technology and has been instrumental in forming its strategic direction over the past eight years. She was awarded her NACD Director Certificate in 2006, and has been a frequent speaker and presenter at many technology functions and seminars across the United States. 23
  • 24. Nov 2011 24
  • 25. CONTACT INFO: For more information, please contact: Anthony Scalese ascalese@zynexmed.com Zynex, Inc. 9990 Park Meadows Drive Lone Tree, CO 80124 Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynexmed.com 25